Spots Global Cancer Trial Database for lucitanib
Every month we try and update this database with for lucitanib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | NCT01283945 | Solid Tumors | Lucitanib | 18 Years - | Servier | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Study of the AL3810 in the Treatment of Advanced Solid Tumor | NCT03117101 | Advanced Solid ... | Lucitanib | 18 Years - 70 Years | Haihe Biopharma Co., Ltd. | |
| A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer | NCT02053636 | Breast Cancer | lucitanib | 18 Years - | Servier | |
| Study of the AL3810 in the Treatment of Advanced Solid Tumor | NCT03117101 | Advanced Solid ... | Lucitanib | 18 Years - 70 Years | Haihe Biopharma Co., Ltd. | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer | NCT02053636 | Breast Cancer | lucitanib | 18 Years - | Servier | |
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | NCT01283945 | Solid Tumors | Lucitanib | 18 Years - | Servier | |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | NCT03992131 | Ovarian Cancer Triple-negative... Urothelial Carc... Solid Tumor | Rucaparib Lucitanib Sacituzumab gov... | 18 Years - | pharmaand GmbH | |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | NCT04042116 | Advanced Solid ... Gynecologic Can... | Lucitanib Lucitanib Lucitanib Nivolumab | 18 Years - | Clovis Oncology, Inc. | |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | NCT04042116 | Advanced Solid ... Gynecologic Can... | Lucitanib Lucitanib Lucitanib Nivolumab | 18 Years - | Clovis Oncology, Inc. | |
| Study of the AL3810 in the Treatment of Advanced Solid Tumor | NCT03117101 | Advanced Solid ... | Lucitanib | 18 Years - 70 Years | Haihe Biopharma Co., Ltd. | |
| Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations | NCT02747797 | Advanced Cancer | Lucitanib | 18 Years - | University of California, San Diego |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
